Microbial Manufacturing Our Offerings Biocina Quality isn’t just a goal — it’s embedded in our culture and drives everything we do. as the only biologics cdmo in australia approved by the us fda, biocina stands apart in capability and compliance. partner with us and watch your life’s work thrive. Biocina is a global end to end biologics contract development and manufacturing organisation (cdmo), offering highest quality, cost effective cell line, process, analytical and formulation development, and cgmp clinical & commercial manufacturing of the microbial, pdna and mrna modalities.
Biocina Ausbiotech Biocina will be attending ausbiotech 2025!. Become a member of ausbiotech to strengthen your connections in the australian life sciences industry, benefit from longstanding relationships across government, industry and academia, shape advocacy efforts and help foster a sustainable and globally competitive sector. Biocina and novacina strategic merger forms end to end cdmo with seamless services from cell line development to commercial manufacturing in australia. The merger integrates biocina's expertise in process development and manufacturing for the microbial, plasmid dna, and mrna modalities at the adelaide facility with novacina's perth facility.
Biocina Ausbiotech Biocina and novacina strategic merger forms end to end cdmo with seamless services from cell line development to commercial manufacturing in australia. The merger integrates biocina's expertise in process development and manufacturing for the microbial, plasmid dna, and mrna modalities at the adelaide facility with novacina's perth facility. “as australia’s leading cdmo focused on delivering critical mrna manufacturing capabilities, we are delighted to welcome biocina formally to adelaide as a flagship of the national mrna landscape,” added minister patterson. The combined company, which will retain the biocina name, will be fully integrated to provide the market a seamless, end to end offering, from cell line development and process development, to clinical and commercial drug substance and sterile fill finish of drug products. Two australian cdmos, biocina and novacina, have announced a strategic merger to operate as a single contract manufacturing company under the biocina name. Biocina, a global contract development and manufacturing organisation (cdmo), has announced a strategic merger with novacina. the merger integrates both companies’ expertise to deliver a seamless suite of end to end manufacturing solutions for the biopharmaceutical and small molecule industries.
Biocina Ausbiotech “as australia’s leading cdmo focused on delivering critical mrna manufacturing capabilities, we are delighted to welcome biocina formally to adelaide as a flagship of the national mrna landscape,” added minister patterson. The combined company, which will retain the biocina name, will be fully integrated to provide the market a seamless, end to end offering, from cell line development and process development, to clinical and commercial drug substance and sterile fill finish of drug products. Two australian cdmos, biocina and novacina, have announced a strategic merger to operate as a single contract manufacturing company under the biocina name. Biocina, a global contract development and manufacturing organisation (cdmo), has announced a strategic merger with novacina. the merger integrates both companies’ expertise to deliver a seamless suite of end to end manufacturing solutions for the biopharmaceutical and small molecule industries.
Comments are closed.